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Background: Patient-centered diabetes care requires shared decision making (SDM). Decision aids promote SDM,
but their efficacy in nonacademic and rural primary care clinics is unclear.
Methods: We cluster-randomized 10 practices in a concealed fashion to implement either a decision aid (DA)
about starting statins or one about choosing antihyperglycemic agents. Each practice served as a control group for
another practice implementing the other type of DA. From April 2011 to July 2012, 103 (DA=53) patients with type
2 diabetes participated in the trial. We used patient and clinician surveys administered after the clinical encounter
to collect decisional outcomes (patient knowledge and comfort with decision making, patient and clinician
satisfaction). Medical records provided data on metabolic control. Pharmacy fill profiles provided data for estimating
adherence to therapy.
Results: Compared to usual care, patients receiving the DA were more likely to report discussing medications
(77% vs. 45%, p<.001), were more likely to answer knowledge questions correctly (risk reduction with statins 61% vs.
33%, p=.07; knowledge about options 57% vs. 33%, p=.002) and were more engaged by their clinicians in decision
making (50. vs. 28, difference 21.4 (95% CI 6.4, 36.3), p=.01). We found no significant impact on patient satisfaction,
medication starts, adherence or clinical outcomes, in part due to limited statistical power.
Conclusion: DAs improved decisional outcomes without significant effect on clinical outcomes. DAs designed for
point-of-care use with type 2 diabetes patients promoted shared decision making in nonacademic and rural
primary care practices.
Trial Registration: NCT01029288
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Shared decision making (SDM) is a patient-centered ap-
proach to improve the quality of care of patients with
diabetes and other chronic conditions [1]. Patient deci-
sion aids are tools designed to convey information about
available options and their relative advantages and dis-
advantages to patients [2]. These decision aids, when
designed for use during the consultation, create conver-
sations that engage patients in making treatment deci-
sions [3]. In close collaboration with a multidisciplinary* Correspondence: montori.victor@mayo.edu
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reproduction in any medium, provided the orteam, including clinicians and patients with diabetes, we
have developed decision aids to support the choice of
antihyperglycemic agents and about using statins to re-
duce cardiovascular risk [3,4]. In efficacy randomized
trials, these tools increased patient knowledge and en-
gagement of patients in their treatment decisions [5-7].
In addition, self-reported medication adherence was im-
proved in patients using the decision aid for statins [5].
While these trials provided evidence of efficacy of de-
cision aids in patients with diabetes receiving care in
academic clinics, little is known about the effectiveness
of these tools in routine clinical practice, particularly in
rural clinics. In this context of imperfect knowledge,
state legislation in Washington and Minnesota and pro-
visions in the Patient Protection and Affordable CareLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Medicare and Medicaid Services evaluates accountable
care organizations for their ability to implement SDM
[10]. The National Quality Forum recommends measur-
ing SDM as part of its framework for assessing quality of
care in patients with multiple chronic conditions [11].
These legislative efforts require improvements in the evi-
dence base about the effect of implementing SDM in
usual clinical settings.
Thus, the objective of this study was to evaluate, in a
cluster-randomized practical trial enrolling nonacademic
and rural primary care practices and their patients with
type 2 diabetes, the impact of patient decision aids vs.
usual care on decision making measures, metabolic con-
trol and medication adherence.
We opted for a cluster-randomized trial, with rando-
mization at the clinic level in order to reduce the risk of
contamination, mitigate confounding with clinician
communication style, and facilitate the implementation
of study procedures and of the decision aid in each prac-
tice [12].Methods
We conducted a multicenter cluster randomized con-
trolled trial set in nonacademic and rural primary care
practices. These practices are affiliated either with
Olmsted Medical Center (OMC) or the Mayo Clinic,
and are located in Southeastern Minnesota, USA.
Mayo Clinic and Olmsted Medical Center Institutio-
nal Review Boards approved the study protocol and
all study procedures. These procedures appear in de-
tail elsewhere [13] and we present these here briefly.Participants
Eligible participants were physicians, nurse practitioners,
and physician assistants (i.e., clinicians) who cared for
patients with type 2 diabetes at participating primary
care practices. Practices were deemed eligible if they
provided primary care for patients with type 2 dia-
betes. Minimal training was provided to clinicians that
consented to participate [13]. Eligible patients were
adults with >= 1 year of type 2 diabetes with a rea-
son, identified by their clinician, to consider changing
their antihyperglycemic or lipid-lowering regimens.
For example, for the diabetes discussion, eligible pa-
tients had HbA1C > 7.3, were not using insulin, and
were not taking >2 antihyperglycemic agents at max-
imum dose. For the discussion about statins, eligible
patients should not be using statins and should not
have contraindications for taking statins. All patients
and clinicians signed written informed consent for
participation.Approach and protection against bias
Primary care practices were enrolled then matched by
size (≤ 2 clinicians or > 2 clinicians) and randomly allo-
cated by a statistician (who was the only team member
aware of the composition of the pairs of practices) to i)
the use of the Diabetes Medication Choice decision aid
and usual care for lipid therapy medication (statin) dis-
cussion during the encounter or to ii) the use of the
Statin Choice decision aid and usual care for anti-
hyperglycemic medications discussion during the en-
counter [13]. This design allowed for each practice to
incorporate a decision aid within their organization and
for clinicians and their patients to qualify for either arm
or both, while preventing contamination. Patients, who
were kept unaware of the study hypotheses, and their
clinician used the decision aids (http://shareddecisions.
mayoclinic.org, Additional file 1) during the clinical
encounter or proceeded with their encounter as usual
(Figure 1).
Data collection and outcomes
Decisional outcomes
We surveyed patients immediately after the clinical en-
counter with their clinician (and 3 and 6 months later)
to ascertain their knowledge by assessing (a) how many
of the 6 questions about the options and their pros and
cons of antihyperglycemic agents patients answered cor-
rectly (Knowledge Transfer), and (b) how accurately they
estimated their risk of having a heart attack within the
next 10 years with and without statin use, in the statin
group (Knowledge of Risk). Using the post-visit ques-
tionnaire, patients reported their decisional comfort by
responding to the information, efficacy and satisfaction
subscales of the Decisional Conflict Scale [14,15]. They
also reported if a conversation about the pertinent medi-
cations took place, what decision was made about me-
dications, and their satisfaction with the way in which
information was shared.
We used a fidelity checklist created by our team to re-
view video records of encounters to determine the ex-
tent to which clinicians were able to use the decision aid
as intended in the decision aid arm or demonstrated
similar behaviors in the control arm (reflecting potential
contamination). The checklist included a minimum set
(14 elements for the statin decision aid and 12 for the
antihyperglycemic decision aid) that had to be present
during the encounter. A pair of trained and calibrated
investigators working independently and reproducibly
(concordance correlation coefficient [16] = 0.95) evalu-
ated video recorded encounters in intervention and con-
trol groups (when both clinicians and patients consented
to video recording) and, using the OPTION score [17],
assessed the extent to which the clinician was able to en-
gage the patient in decision making about medications.
Figure 1 Study design for clinical trial.
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patients about the implementation of their decision after
the index encounter. The clinicians’ survey administered
after the encounter inquired about what decision was
made regarding medication during the encounter, and in
the DA arm, the providers’ thoughts on the ease of use
of the DA and the ease of incorporating it into practice.
Clinical outcomes
Medical records were reviewed at patient enrollment
and at nine months post encounter. From the medical
record, we extracted the patient’s medication list includ-
ing medications added or changed during the index en-
counter and key laboratory parameters such as HbA1c
and lipid profile. In patients who had a discussion about
diabetes medications, we coded the HbA1c at enrollment
and six months post-enrollment as < 8%, 8-9% and >9%.
Using the change in categories in this six-month period,
we classified patients as having no change, a decrease,
or an increase in glycemia. Similarly, we compared
the change in LDL-cholesterol levels at six months vs.
baseline, with categories drawn at below 5.55 mmol/L(100 mg/dL) or 5.55 mmol/L or greater, classifying
patients as having had no change, an increase, or a
decrease in LDL-cholesterol level.
We used pharmacy records for the 12-month period,
starting 3 months prior to the study encounter and
spanning up to nine months after it; to estimate adher-
ence to medications added or changed during the index
encounter. This estimate of adherence was calculated
using the percentage of days covered (PDC) of 180 days
post the clinical encounter with their clinician, defined
as the number of days a patient had a supply of each
medication divided by the number of days of eligibility
for that medication. We also calculated the proportion
of patients who were adherent (defined as PDC cov-
ered ≥80% of days) to that study drug throughout the
follow-up period.
Analyses
We planned to enroll 240 patients from 8 practices (30
patients per practice, 120 patients per arm) in order to
have 90% power to detect a difference of 9.8 points in
decisional comfort between the usual care arm and the
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suming an intracluster correlation coefficient (ICC) of
0.05 [18]. Patient demographic characteristics were com-
pared using a Fisher’s exact test for categorical variables
and a Wilcoxon rank sum test for continuous variables.
A regression model was used to adjust all continuous
outcomes (decisional comfort post encounter and PDC)
adjusting for both arm and type of discussion (diabetes
medication or statins). We report adjusted means with
95% confidence intervals. For binary results (≥ 80% ad-
herence), a logistic model was used to adjust for arm
and type of discussion with odds ratios and 95% confi-
dence intervals reported. The ICC’s were 0 or nearly so
for all outcomes (knowledge, decisional comfort, medi-
cation adherence), indicating no clustering, so analyses
were not adjusted for clustering. Furthermore, in a sec-
ondary analysis, all results were the same after adjusting
for clustering (data not shown).
Secondary outcomes of satisfaction with knowledge
transfer, change in laboratory values, and post-index visit
cardiovascular risk knowledge (statin discussion only)
were compared using a Fisher’s exact test. The post-
index visit, 3 and 6 months knowledge (diabetes medica-
tion discussion only) was compared using the Wilcoxon
rank sum test.
Study data were recorded and managed using the
Research Electronic Data Capture (REDCap) system
[19]. All analysis and data management were conduc-




(usual care comparator for Statin Decision Aid)3
(N=5 Sites)
Enrolled patients = 27 DA/38 UC (2 DA & UC)
Median per site: 10 (range 3, 28)
Decline = 65  Median per site:  7 (range 1, 43)
Reason: Unable to reach (48)
Not interested (10)
Other (5) 
DA = decision aid; UC = usual care
1 – All sites assessed for eligibility agreed to participate and were rando
2 – 2 patients removed after aspirin arm of trial was dropped from study
3 – 2 patients enrolled in both arms were excluded from analysis 
4 – 2 patients enrolled in both arms were excluded from analysis (1 is a
Evaluable for analysis:N=65 (27 DA) 
Missing follow-up: n (DA)
Patient Baseline Survey – 1 (0) 
Clinician Survey – 1 (1) 
Patient 3 month survey – 13 (7) 
Patient 6 month survey – 14 (8) 
Figure 2 Flow diagram for clinical trial.Results
In the funded timeframe for this study, we could not en-
roll our target sample, but 110 patients were enrolled
between April 2010 and July 2011 (Figure 2). We in-
cluded 103 patients in the analysis, N=53 in the decision
aid (DA) arm and N=50 in the usual care (UC) arm. We
excluded 2 ineligible patients incorrectly enrolled (ex-
cluded without knowledge of their allocation or outcome
[20]), and 2 patients enrolled to the usual care arm of
the aspirin decision aid (an arm that was discontinued
early in the trial due to poor feasibility without any pa-
tients allocated to the intervention arm [13]). In a proto-
col deviation and before examining the results, we also
excluded 4 patients who were correctly allocated to both
DA and UC; because we did not get enough patients in
that situation to afford a separate analysis we present
their results in Additional file 2.
All patient factors were well balanced across both arms
with a difference found in the type of discussion that pa-
tients had (statins vs. diabetes medication; Table 1); subse-
quent results adjust for this difference. Forty-one clinicians
participated in the trial, 27 participated in the diabetes
medication group and 33 in the statin group (Table 2).
Decisional outcomes - patient outcomes
Decision aid use significantly increased knowledge transfer
at baseline (Table 3). Patients were similarly satisfied with
usual care and the decision aid; 71% of decision aid pa-
tients found the information provided helpful compared




 post randomization exclusion) and 1 UC  patient was incorrectly enrolled. 
Statin Decision Aid
(usual care comparator for Diabetes Usual Care)4
(N=5 Sites)
Enrolled patients= 26 DA/14 UC (2 DA & UC)
Median per site: 2 (range 2, 28)
Declined = 32  Median per site: 4 (range 1, 17)
Reason: Unable to reach (11)
Not interested (19) 
Other (2) 
Evaluable for analysis:N=39 (26 DA) 
Missing follow-up: n (DA)
Patient Baseline Survey – 3 (1) 
Clinician Survey – 7 (4) 
Patient 3 month survey – 12 (8) 
Patient 6 month survey – 11 (7) 
Table 1 Patient characteristics
Character Characteristics Decision aid (N=53) Usual care (N=50)
n (%) n (%)
Discussion1 Diabetes medications 27 (51) 12 (24)
Statin 26 (49) 38 (76)
Sex Male 37 (70) 26 (52)
Age2: Mean (SD) 57.9 (10.5) 57.3 (11.4)
DM Duration <5 years 24 (45) 29 (58)
5+ years 29 (55) 21 (42)
Race1 White 53 (100) 36 (72)
Other 0 (0) 3 (6)
Unknown 0 (0) 11 (22)
Education2 HS or less 22 (44) 10 (22)
Some college 19 (38) 25 (54)
College + 9 (18) 11 (24)
Marital status3 Married 38 (78) 32 (68)
Divorced/Separated/Widowed 7 (14) 9 (19)
Never married 4 (8) 6 (13)
Income3 <40k 14 (30) 16 (37)
40k or more 33 (70) 27 (63)
Health score2 76.0 (16.1) 74.0 (16.1)
BMI2 37.8 (8.1) 34.7 (10.1)
HbA1c2,4 8.7 (1.6) 8.0 (0.6)
7-8 13 (48) 8 (67)
>8 14 (52) 4 (33)
LDL2,5 103.2 (26.6) 105.2 (41.5)
<100 12 (46) 18 (47)
Blood pressure <130/80 30 (57) 30 (60)
MI Risk2,5 21.0 (12.0) 16.8 (12.4)
Abbreviations: DM Diabetes Mellitus, HS High School, MI Myocardial Infarction.
1p<0.05.
2Mean (Standard Deviation).
3Missing values not presented.
4Diabetes Medication discussion patients only.
5Statin Medication discussion patients only.
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arms. Patients receiving the decision aid (diabetes medi-
cation or statin) were more likely to report having had a
discussion to start or change a medication compared to
those receiving usual care (77% vs. UC: 45%, P<.0001;
Table 5), but there was no significant difference in the
likelihood of start or change of a medicine in this group.
In video-recorded encounters (N=39, 22 in the decision
aid arm), clinician effort to engage patients in decision
making was significantly higher in the decision aid arm
with a mean difference of 21.4 points in the OPTION
score (95% CI 6.4, 36.3). We found in video recorded
visits that clinicians used the decision aid with moderate
fidelity, completing on average 66% (95% CI 54, 78) of
the checklist items. Usual care encounters covered 20%(95% CI 10, 29) of the items on the checklist, indicating
minimal if any contamination (Table 5).
Decisional outcomes - clinician outcomes
Clinicians using the decision aids were more likely to re-
port having had a conversation about starting or chan-
ging a medication with the patient (Table 6). There was
greater agreement amongst patients and clinicians using
decision aids on whether a conversation occurred or not
regarding medications, but the difference in the fre-
quency of concordance was not significant (74% vs. 64%,
p=.30). Clinicians that administered the decision aids
found them easy to very easy to use (80%), and 80%
reported that it was easy to very easy for their staff to in-
tegrate decision aids into the practice workflow.
Table 2 Clinician characteristics
Character Characteristics N=41
N (%)
Clinicians per site1 3.7, 2 (1, 14)
Arm UC 25 (61)
DA 35 (85)
Discussion Diabetes medications 27 (66)
Statin 33 (80)
Type of clinician2 Provider 27 (66%) [23]
Resident/Fellow 7 (17%) [6]
NP/PA 7 (17%) [6]
Gender Male 24 (59)
Age1,4 44.6, 46.5 (28, 60)
Race White 39 (95)
Asian 1 (2.5)
NH/PI 1 (2.5)
Years in practice1,4 14, 13.5 (1, 42)
Abbreviations: NP Nurse Practitioner, PA Physician Assistant, NH Native
Hawaiian, PI Pacific Islander.
1Mean, Median (Range).
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There was no difference in the proportion of patients
achieving improved glycemic control in the decision
aid or usual care arm (44% vs. 50%, p=.25); both arms
achieved similar levels of LDL cholesterol (Table 7).
Twenty five out of 30 (83%) patients within the decision
aid arm that received a prescription filled the prescrip-
tion (Table 7), compared to 22 of 22 patients (100%) in
the usual care arm. The fill rate for statins was 100% in
both arms; all non-starts were seen within the patients
that had a diabetes medication discussion. No differenceTable 3 Decisional outcome - knowledge assessment
Decision aid
Knowledge transfer at baseline1,2, N 27
Mean (95% CI) 56.8 (49.4, 64.2)
Knowledge transfer at 3 months1,2, N 20
Mean (95% CI) 56.7 (47.4, 65.9)
Knowledge transfer at 6 months1,2, N 19
Mean (95% CI) 56.1 (48.5, 63.8)
Knowledge of Risk w/out medication3,4,5,6 12 (52%)
Knowledge of Risk w/ medication3,4,5,6 14 (61%)
*p<0.05.
1Diabetes medication discussion only.
2% correct out of total asked (N=6 questions).
3Statin discussion only.
4Response to risk knowledge was correct.
5Missing 5 responses (DA=3, UC=2).
6Relative risk and 95% confidence interval.was found in PDC overall or within each discussion
group. In the statin arm of the trial, we found no signifi-




Compared to usual care, patients participating in en-
counters using decision aids were more likely to report
participating in a conversation about medications, gained
more knowledge about the options, and were more likely
to have their clinician put effort into engaging them in the
decision making process. There was no significant impact
on patient satisfaction, on choice of starting or adhering
to medicines and on measures of metabolic control; these
estimates, though, were imprecise due to low statistical
power.
Limitations and strengths
This trial was smaller than planned mostly due to chal-
lenges in the timely recruitment of clinicians and prac-
tices; this reduced the precision with which we were able
to estimate the intervention effect on clinical outcomes.
We were able to obtain video recordings from 38% of
encounters. This limits our ability to use our checklist
and to obtain an OPTION score in all encounters thus
reducing our confidence in the inferences related to fi-
delity and clinicians’ efforts to engage patients in deci-
sion making, respectively. Clinicians and staff of rural
primary care clinics generously engaged in this study,
seeking with the study team to overcome challenges re-
lated to distance and sparse eligible patients. The infre-
quent opportunity to use the decision aids coupled with
our tactic to provide minimal training to clinicians in
the use of the decision aids led to only a few patients re-
ceiving the decision aid as intended (~30% of encountersUsual care Mean diff (95% CI)
10
33.3 (20.8, 45.9) 23.5 (9.7, 37.3)
8
50.0 (35.1, 64.9) 6.7 (−9.9, 23.2)
8
54.2 (36.3, 72.0) 2.0 (−13.3, 17.3)
16 (44%) 1.2 (0.7, 2.0)
12 (33%) 1.8 (1.0, 3.2)
Table 4 Decisional outcome - satisfaction with knowledge transfer1,2
Category Decision aid (N=40) Usual care (N=21) p-value3
Amount of information Just right 32 (84%) 15 (75%) 0.50
Too little 1 (3%) 2 (10%)
Too much 5 (13%) 3 (15%)
Clarity of information Extremely 22 (58%) 10 (50%) 0.45
Somewhat 16 (42%) 9 (45%)
Not clear 0 (0%) 1 (5%)
Helpfulness of information Extremely 27 (71%) 10 (53%) 0.17
Somewhat 11 (29%) 9 (45%)
Not helpful 0 (0%) 1 (5%)
Would want for other decisions For sure 22 (58%) 13 (65%) 0.30
Not sure 16 (42%) 6 (30%)
Not at all 0 (0%) 1 (5%)
Recommend to others Strongly for 24 (63%) 12 (60%) >.99
Not sure 14 (37%) 8 (40%)
Strongly against 0 (0%) 0 (0%)
1Of those that felt a discussion took place.
2Missing responses: DA=2, UC=1.
3Fisher exact test statistic p-value.
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not appreciate important clustering effects, our trial has
all the challenges of clustered-randomized trials in that
the small number of clusters reduces the likelihood that
randomization will achieve balanced prognosis. Also, in-
complete recruitment of clinicians and patients within
each cluster might introduce selection bias, particularly
through incomplete allocation concealment once sites
have been allocated but clinicians and patients are still
being recruited.
On the other hand, our inferences are strengthened by
concealed randomization of practices and blinding of pa-
tients (to the hypotheses of the study), data collectors
and analysts (to allocation), and by protecting the results
from confounding by contamination and poor fidelity.Table 5 Decisional outcome - decision and comfort with decis
Decis
Had a discussion about starting or changing a medication 40
Decided to start/change a medication1 13
Comfort of decision (DCS)1,2 82.9 (7
Perception of knowledge (DCS subscale)1,2 80.5 (7
Adequacy of support (DCS subscale)1,2 80.9 (7
Effect (DCS subscale)1,2 86.4 (8
Level of patient engagement (OPTION)2,3 49.7 (4
Fidelity2,3 65.7% (5
1Of those that had a discussion.
2Adjusted Mean (95% CI). Regression model of arm and type of discussion (diabete
339 patients that consented to video analysis (DA=22, UC=17).The consistency of our findings here with findings in ef-
ficacy trials, particularly on decisional outcomes, further
strengthens our inferences. The effects of SDM on cli-
nical outcomes, however, remain unclear.
Comparison with prior research
This study, along with others we have conducted, has
found improvements in knowledge, decisional comfort,
and patient participation in decision making, and little
impact on adherence and other patient health outcomes.
The Diabetes Medication Choice study [6] found a sig-
nificant increase in knowledge over usual care (adjusted
mean difference 1.10 (95% CI 0.11, 2.09), an increase of
patient involvement on average of 21.8 of 100 points,
but no impact on medication adherence at 6 months norion
ion aid Usual care Relative risk (95% CI)
(77%) 21 (45%) 1.8 (1.2, 2.5)
(33%) 9 (43%) 0.8 (0.4, 1.5)
Mean difference (95% CI)
8.8, 87.0) 81.2 (75.3, 87.1) 1.7 (−5.3, 8.7)
5.1, 85.9) 74.9 (67.1, 82.6) 5.6 (−3.6, 14.8)
6.1, 85.8) 81.0 (74.1, 87.9) −0.05 (−8.3, 8.2)
2.3, 90.5) 86.1 (80.2, 91.9) 0.29 (−6.7, 7.3)
0.6, 58.7) 28.3 (15.1, 41.6) 21.4 (6.4, 36.3)
3.8, 77.6) 19.6% (9.9, 29.3) 46.1% (30.3, 61.8)
s medication vs. statin).










Had discussion about starting or
changing a medication
44 (90%) 32 (68%) 1.3 (1.1, 1.6)
Decided to start/change a
medication1
14 (32%) 6 (19%) 1.7 (0.7, 4.0)
Agreement between clinician and
patient on having a discussion1
34 (74%) 23 (64%) 1.2 (0.9, 1.6)
Clinician view of DA N=40 ~
Delivery of DA was:
Easy to very Easy 32 (80%) ~
Neither 4 (10%) ~
Difficult to very difficult 4 (10%) ~
Integration of DA was2:
Easy to very easy 32 (80%) ~
Neither 7 (18%) ~
Difficult to very difficult 0 (0%) ~
1Of those that had a discussion.
2Missing 1 response.
Table 7 Clinical outcomes - lab results and medication
adherence
Decision aid Usual care p value5
Lab results
HbA1c1 0.25
No change 12 (48%) 3 (25%)
Increase 2 (8%) 3 (25%)
Decrease 11 (44%) 6 (50%)
LDL2 0.57
No change 13 (68%) 14 (52%)
Increase 1 (5%) 2 (7%)
Decrease 5 (26%) 11 (41%)
Medication adherence results
Decided to start or change a
medication
13 (33%) 9 (43%) 0.58
Prescription data was obtained 43 (81%) 44 (88%)
Has a prescription for
medication
30 (57%) 22 (44%)
Diabetes 25 (83%) 11 (50%)
Statin 5 (17%) 11 (50%)
Filled prescription for
medication
25 (83%) 22 (100%)
Diabetes 20 (80%) 11 (100%)
Statin 5 (100%) 11 (100%)
# of medications filled 49 28
Diabetes3 44 17
Statin 5 11
Percentage of days covered
≥ 80%
38 (78%) 22 (79%) >.99
Diabetes 34 (77%) 15 (88%) 0.48
Statin 4 (80%) 7 (64%) >.99
Percentage of days covered
≥ 80%4
1.44 (0.5, 4.1) 1 (Ref.) 0.49
1Diabetes medication discussion patients only.
2Statin medication discussion patients only.
3Patients taking multiple diabetes medications.
4Odds ratio (95% CI), logistic model of discussion and arm.
5Fisher’s exact test statistic (unless noted otherwise).
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domized trial [5] conducted in a specialty setting found
that patients who received the decision aid were 22.4
times more likely to know their estimated cardiovascular
risk than those in the usual care group, had greater deci-
sional comfort (10.6 points higher on a 100 point scale),
and better self-reported adherence at 3 months, odds
ratio 3.4 (95% CI 1.5, 7.5). The second Statin Choice
clinical trial [7] conducted by another group found an
increase in patient knowledge of their cardiovascular risk
as well (odds ratio 1.9, 95% CI 1.0, 3.8), an increase in
decisional comfort among the informed subscale and
support subscale, and no difference in medication adhe-
rence at six months. Our findings, while imprecise, are
consistent with these prior results suggesting it is fea-
sible to observe similar outcomes in academic and nona-
cademic practices, provided that the decision aids are
implemented.
Implications for policy, practice and research
We have been able to conduct trials of decision aids for
use during the consultations of people with diabetes in
academic subspecialty and primary care and, in this
study, in nonacademic and rural primary care settings.
In these contexts, the decision aids have been well re-
ceived by patients and clinicians, and have improved de-
cisional outcomes. This effectiveness has not necessarily
translated into a favorable impact on clinical measures
of effect or on medication adherence. We have seen this
not only here, but also in our prior studies and on therecent Cochrane review of decision aids [2]. This might
result from two closely related issues. The first issue is
that decision aids that operate during the consultation
require attending the consultation, itself a manifestation
of adherence. Thus, without invoking trial selection bias,
the requirement for our decision aids to operate in the
consultation may limit their exposure to non-adherent
patients. This limits the opportunity to find effects on
medication adherence. The second closely related issue
is that shared decision making is appropriate when there
is more than one sensible management option. When
one option yields superior outcomes with acceptable
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tion, and the outcomes achieved by the group will reflect
the effect of each patient implementing that option. Any
variability observed across patients will result from
chance, differences in biological response, and treatment
adherence. When more than one option is acceptable,
however, the effect of different patients opting for differ-
ent treatments will contribute to the overall variability in
outcomes. Therefore, in the absence of a superior treat-
ment choice, the only way shared decision making can im-
prove patient outcomes is through improvements in
adherence to the selected treatment option. Thus, there is
no a priori reason to believe that shared decision making
should improve clinical outcomes beyond its effect on ad-
herence to treatment.
Research to select patients most likely to benefit from
SDM and to explore ways to improve high-fidelity deliv-
ery of the tools may improve their clinical utility. We
have discussed above that the observed fidelity of use
could suggest that some effectiveness might not have
been realized because of insufficient clinician training.
An alternative explanation is that patient-centered care
sometimes necessitates deviation from the expected use
of the tools in order to accommodate emerging patient
issues. Whether this means that more effort to improve
optimal use of the tools is necessary warrants further
exploration.
Despite the uncertainty about their impact on clinical
outcomes, the value of decision aids as promoters of
patient-centered practice and patient engagement re-
mains, in our view, the most important justification for
their use. DAs promote patient-centered practice to the
extent that they support both parties in having an
evidence-based discussion in which patient participation
in deliberation is dynamically and empathically nego-
tiated by the parties. DAs do not guarantee patient-
centered care to the extent that the practices, norms,
rituals, and policies of the practice may fail to support it
[21]. Similarly, patient engagement is facilitated by the
common ground offered by the decision aid, but it might
not happen if the patient is not in a position to partici-
pate or feels threatened by such participation [22]. Thus,
DAs are tools to promote and facilitate participatory
forms of decision making, but much work is needed to
increase the likelihood that shared decision making re-
sults from their use.
We do not think the results from this and past trials
will satisfy those pursuing legislation of SDM seeking re-
ductions in healthcare utilization and costs [23]. To this
extent, the Patient Protection and Affordable Care Act
of 2010 did not fund, but promoted the establishment
of SDM Resource Centers. The act also created the
Patient-Centered Outcomes Research Institute (PCORI)
that funds comparative effectiveness research andcommunication of evidence through SDM [9]. In our
view, current federal policy strikes the right balance,
supporting additional research rather than mandating im-
plementation. State legislatures, however, have been more
sanguine in their approach [8]. Clearly large studies out-
side of academia will be needed to know the full extent of
intended and unintended consequences of SDM.
Conclusion
This small trial to examine the effectiveness of decision
aids in nonacademic and rural clinical practices revealed
(a) difficulties in recruitment of clinicians (and their pa-
tients), (b) a need to train and support clinicians in the
use of the decision aids, (c) that using decision aids is in-
deed feasible in the care of patients with type 2 diabetes
in these clinics, and (d) point-of-care decision aids are
effective in improving the quality of decision making in
the care of this patients.
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